TrianglePUBLICATIONS · 34138471
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer
- Publication date
- 2021 Sep 15
- First author
- Sasaki K
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Sasaki K
- type
- Author
- name
- Kantarjian HM
- type
- Author
- name
- Morita K
- type
- Author
- name
- Short NJ
- type
- Author
- name
- Konopleva M
- type
- Author
- name
- Jain N
- type
- Author
- name
- Ravandi F
- type
- Author
- name
- Garcia-Manero G
- type
- Author
- name
- Wang S
- type
- Author
- name
- Khoury JD
- type
- Author
- name
- Jorgensen JL
- type
- Author
- name
- Champlin RE
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Sasaki K
- type
- Author
- name
- Kantarjian HM
- type
- Author
- name
- Morita K
- type
- Author
- name
- Short NJ
- type
- Author
- name
- Konopleva M
- type
- Author
- name
- Jain N
- type
- Author
- name
- Ravandi F
- type
- Author
- name
- Garcia-Manero G
- type
- Author
- name
- Wang S
- type
- Author
- name
- Khoury JD
- type
- Author
- name
- Jorgensen JL
- type
- Author
- name
- Champlin RE
- type
- Author
- bibliography ids
- nci-bib-65e611ffa1e4424791102f7d
- book metadata
- content sha256
- 35461d29d7ab8ef135d7a9c671eeb28b8d7f01316b5a89dff272b632d30bfeec
- document type
- citation
- dois
- 10.1002/cncr.33655
- electronic publication date
- display
- 2021 Jun 17
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34138471
- immutable id
- pubmed:34138471@35461d29d7ab8ef135d7a9c671eeb28b8d7f01316b5a89dff272b632d30bfeec
- journal
- abbreviation
- Cancer
- issn electronic
- 1097-0142
- issn print
- 0008-543X
- issue
- 18
- name
- Cancer
- nlm unique id
- 0374236
- pages
- 3381-3389
- volume
- 127
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34138471
- provenance
- batch id
- 192b6392c165c6b06274
- provider
- NCBI PubMed ESummary
- record sha256
- 8392d2d7eca61c848b21818aa217c66fb4acc8c40896ad06bbe088cda6fa3f09
- response sha256
- 7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
- retrieved at
- 2026-09-09T23:48:02.713075+00:00
- publication date
- display
- 2021 Sep 15
- precision
- day
- year
- 2021
- publication types
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Preserved source evidence · Not medical advice